Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...
Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop ...
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...
Tel Aviv, Israel (ots/PRNewswire) - Syqe Medical, the developer of innovative technologies in the world of medical devices, is pleased to announce the signing of an agreement with the Israeli Ministry of Defence to supply the SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis by inhalation ...
London (ots/PRNewswire) - - Aim is to prevent avoidable heart attacks and strokes in North London - Expands primary care capacity by utilising digital tools to identify and manage high risk individuals - Advances proactive, predictive care for people at risk of the world's leading cause of death1 Huma Therapeutics ...
Schweizerischer Nationalfonds / Fonds national suisse
New York (ots/PRNewswire) - Huma's predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education Huma Therapeutics Limited ("Huma"), a leading global digital health company, and Bayer, a leading global life sciences company, have ...
Schweizerische Multiple Sklerose Gesellschaft
London (ots/PRNewswire) - - PlumCare RWE and Lifebit enter a three-year partnership to support Greece's pioneering national newborn genomic sequencing program, BeginNGS. - Researchers will be able to access and analyse data securely in combination with global cohorts, whilst ensuring data is kept safe, private and in place in their secure environment using Lifebit's ...
London (ots/PRNewswire) - - More than 90% of 2,524 participants invited to join a fully virtual COVID-19 study, run by Cambridge researchers, downloaded and registered on the study app1 - Around 75% of participants completed digital biomarker assessments such as resting heart rate, temperature and oxygen saturation at least once per week1 - Participants were aged 45 - ...
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
London and Frankfurt, Germany (ots/PRNewswire) - - Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years - Creates new and advanced digital solutions across all phases of clinical trials - Accelerates patient recruitment and the development of new ...
Huntingdon Valley, Pa. (ots/PRNewswire) - Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with ...
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
San Antonio (ots/PRNewswire) - - The HER2DX® risk score predicted long-term survival outcomes in clinically low-risk patients in APT and ATEMPT clinical trials. - The HER2DX® pCR score predicted response to chemotherapy in combination with trastuzumab and pertuzumab in DAPHNe and GOM clinical trials. - HER2DX®️ is the first genomic test in the world specialized in ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - New findings from NRP 72, financed by the Swiss National Science Foundation, are helping to curb antibiotic resistance. In the field of new antibiotics, however, structures needed for translating results into practice are lacking. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. As antibiotics lose their efficacy, infections that were once easy to treat can give rise to fatal ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
Petach Tikvah, Israel (ots/PRNewswire) - With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. Medison Pharma ("Medison"), a global pharma company focused on providing access to ...
Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...
The International Osteoporosis Foundation (IOF)
Huntingdon Valley, Pa. (ots/PRNewswire) - These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. Menarini ...
Leiden, Netherlands (ots/PRNewswire) - Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days ...
Essen, Germany (ots/PRNewswire) - - Evonik to produce commercial quantities of the drug substance vonoprazan for use in VOQUEZNA™ TRIPLE PAK™ and DUAL PAK™, and other products containing vonoprazan - Supply security through production at sites in Europe and North America - Agreement strengthens Evonik's track record as leading contract development and ...